Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMRN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$9.11+0.9%$0.50$1.07▼$21.00$3.70B1.3870,272 shs262,233 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin-1.48%+6.84%-4.02%-18.18%-56.59%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMRNAmarin0.1559 of 5 stars0.02.00.00.02.40.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMRNAmarin 3.00BuyN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMRNAmarin$228.61M16.36N/AN/A$1.35 per share6.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMRNAmarin-$59.11M-$0.20N/AN/AN/A-16.33%-7.22%-4.96%5/7/2025 (Estimated)Latest AMRN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025AMRNAmarin-$0.06N/AN/AN/AN/AN/A3/12/2025Q4 2024AMRNAmarin-$1.20-$2.40-$1.20-$0.12$32.37 million$62.31 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMRNAmarinN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMRNAmarinN/A3.232.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMRNAmarin22.25%Insider OwnershipCompanyInsider OwnershipAMRNAmarin1.96%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMRNAmarin360410.67 million402.62 millionOptionableAMRN HeadlinesRecent News About These CompaniesAmarin trading halted, news pendingApril 11 at 2:32 AM | markets.businessinsider.comEh Phouthong tips big things for Theara, Amarin title defencesApril 10 at 3:19 AM | phnompenhpost.comAmarin confirms effective data for 1-for-20 ADS ratio changeApril 9 at 5:17 PM | markets.businessinsider.comAmarin Confirms Effective Date for 1-For-20 ADS Ratio ChangeApril 9 at 7:30 AM | globenewswire.comAmarin Confirms Effective Date for 1-For-20 ADS Ratio ChangeApril 9 at 7:30 AM | globenewswire.comStockNews.com Begins Coverage on Amarin (NASDAQ:AMRN)April 9 at 2:14 AM | marketbeat.comAmarin Appoints JEC Capital Partners’ Michael Torok to Board of DirectorsApril 7, 2025 | finance.yahoo.comAmarin Appoints JEC Capital Partners' Michael Torok to Board of DirectorsApril 7, 2025 | globenewswire.comAmarin presents data at ACC.25 on EPA in lipoprotein-enriched plasmaApril 1, 2025 | markets.businessinsider.comAmarin (NASDAQ:AMRN) Earns Sell Rating from Analysts at StockNews.comMarch 31, 2025 | marketbeat.comAmarin Co. plc (NASDAQ:AMRN) Short Interest Down 35.4% in MarchMarch 30, 2025 | marketbeat.comAmarin Stock Set to Reverse Split on Friday, April 11th (NASDAQ:AMRN)March 26, 2025 | marketbeat.comAmarin (NASDAQ:AMRN) Coverage Initiated by Analysts at StockNews.comMarch 23, 2025 | marketbeat.comAmarin shareholder group urges board to initiate strategic reviewMarch 21, 2025 | markets.businessinsider.comAmarin announces additional in vitro data with EPA to be presentedMarch 20, 2025 | markets.businessinsider.comAmarin gains amid shareholder group push for strategic reviewMarch 19, 2025 | seekingalpha.comConcerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of UnderperformanceMarch 19, 2025 | businesswire.comNew Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & ExpoMarch 19, 2025 | globenewswire.comAmarin (NASDAQ:AMRN) Cut to Sell at StockNews.comMarch 15, 2025 | marketbeat.comAmarin Corporation plc (NASDAQ:AMRN) Q4 2024 Earnings Call TranscriptMarch 14, 2025 | msn.comAMRN's Q4 Earnings Lag Estimates, Stock Down on Ratio Change PlanMarch 13, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAMRN Company DescriptionsAmarin NASDAQ:AMRN$9.11 +0.08 (+0.89%) As of 01:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas JPMorgan is a Buy, if You Can Handle The Volatility Rocket Lab Stock: Weathering the Storm, Time for a Comeback? United States Steel's Crash: An Unmissable Buying Opportunity Micron Tumbles on Tariff Threat: Risk/Reward Outlook Improves Is Archer Aviation’s Stock Price Dip a Gift? Marvell Gets Tariff Lifeline But Expect More Volatility Snowflake Boosts Growth by Doubling Down on AI Broadcom's Big Outperformance Shows Strength Amid Tariff Decline Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
